Senators Mark Kelly (D-AZ) and Thom Tillis (R-NC) introduced the bipartisan Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act, legislation to ensure individuals with rare diseases and immunodeficiencies have access to necessary plasma-based medicines.
“The GBS|CIDP Foundation International proudly supports the PLASMA Act and all policies that promote patient access to plasma medicines. Many patients with rare and chronic conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) require reliable access to plasma medicines multiple times per month and any disruption can have devastating effects. Introducing the PLASMA Act is a significant step forward toward ensuring continued access to life-saving plasma medicines into the future,” said Lisa Butler, Executive Director, GBS/CIDP Foundation International.